<DOC>
	<DOCNO>NCT02660502</DOCNO>
	<brief_summary>This double-blind , randomise , three period crossover phase 1 trial use automate 8-hour euglycemic clamp healthy Japanese subject . Each subject randomly allocate one nine sequence receive either three single dose BioChaperone insulin lispro one single dose Humalog® two single dos BioChaperone insulin lispro three separate dose visit . The total trial maximum duration subject 10 week .</brief_summary>
	<brief_title>An Euglycemic Clamp Trial Evaluate Pharmacokinetics Single Doses BioChaperone Insulin Lispro Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Healthy Japanese male female subject completion medical history , physical examination biochemical investigation judge Investigator . BMI 18.5 25.0 kg∙m2 , inclusive . Fasting Plasma Glucose ≤ 5.6 mmol/L ( 100 mg/dL ) . Signed date informed consent obtain trialrelated activity . Known suspect hypersensitivity trial product ( ) relate product . Receipt investigational medicinal product within 3 month randomisation trial . Any history presence life threaten disease ( i.e . cancer except basal cell skin cancer squamous cell skin cancer ) , clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( include type 1 type 2 diabetes mellitus , haematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynaecologic ( female ) , infectious disease , sign acute illness judge investigator . History multiple and/or severe allergy drug food history severe anaphylactic reaction .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>